U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H48N4O8
Molecular Weight 616.7455
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALVESPIMYCIN

SMILES

CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O

InChI

InChIKey=KUFRQPKVAWMTJO-LMZWQJSESA-N
InChI=1S/C32H48N4O8/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40)/b11-9-,19-10+,21-16+/t18-,20+,25+,26+,28-,30+/m1/s1

HIDE SMILES / InChI
Molecular Formula C32H48N4O8
Molecular Weight 616.7455
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Alvespimycin (17-desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin) (17-DMAG; NSC 707545) is an inhibitor of the molecular chaperone heat shock protein HSP90. Alvespimycin is a derivative of antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction. Alvespimycin was studied in clinical trials for the treatment of solid tumors and hematologic malignancies however its development was discontinued.

CNS Activity

CNS Active
4002
Curator's Comment: Alvespimycin (17-DMAG) is brain penetrant and CNS active in animals. No human data available.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 62.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase I
438
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
683.36 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/20111068
24 mg/m² 2 times / week multiple, intravenous
dose: 24 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ALVESPIMYCIN blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2224 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/20111068
24 mg/m² 2 times / week multiple, intravenous
dose: 24 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ALVESPIMYCIN blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
21.49 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/20111068
24 mg/m² 2 times / week multiple, intravenous
dose: 24 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ALVESPIMYCIN blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
DLT: Fatigue, Hypoalbuminemia...
Other AEs: Blood creatinine increased...
Dose limiting toxicities:
Fatigue (grade 3, 25%)
Hypoalbuminemia (grade 3, 25%)
AST increased (grade 4, 25%)
Diarrhea (grade 3, 25%)
Nausea (grade 2, 25%)
Vomiting (grade 2, 25%)
Fever (grade 2, 25%)
Anorexia (grade 2, 25%)
Acute hypotension (grade 4, 25%)
Dehydration (grade 3, 25%)
Hyponatremia (grade 3, 25%)
Acidosis (grade 3, 25%)
Acute renal failure (grade 5, 25%)
Other AEs:
Blood creatinine increased (grade 3, 25%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
24 mg/m2 2 times / week multiple, intravenous
MTD
Dose: 24 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 24 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3-4, 9%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
80 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 80 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 80 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
32 mg/m2 2 times / week multiple, intravenous
Studied dose
Dose: 32 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 32 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
DLT: Acute myocardial infarction, Cardiac ischemia...
Dose limiting toxicities:
Acute myocardial infarction (grade 5, 50%)
Cardiac ischemia (grade 3-4, 50%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
AEs

AEs

AESignificanceDosePopulation
Anorexia grade 2, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Fever grade 2, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Nausea grade 2, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Vomiting grade 2, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Blood creatinine increased grade 3, 25%
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Fatigue grade 3, 25%
DLT
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Hypoalbuminemia grade 3, 25%
DLT
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Acidosis grade 3, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Dehydration grade 3, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Diarrhea grade 3, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Hyponatremia grade 3, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
AST increased grade 4, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Acute hypotension grade 4, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Acute renal failure grade 5, 25%
DLT, Disc. AE
106 mg/m2 1 times / week multiple, intravenous
Highest studied dose
Dose: 106 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 106 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/21278242
Diarrhea grade 3-4, 9%
DLT
24 mg/m2 2 times / week multiple, intravenous
MTD
Dose: 24 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 24 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Cardiac ischemia grade 3-4, 50%
DLT
32 mg/m2 2 times / week multiple, intravenous
Studied dose
Dose: 32 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 32 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Acute myocardial infarction grade 5, 50%
DLT, Disc. AE
32 mg/m2 2 times / week multiple, intravenous
Studied dose
Dose: 32 mg/m2, 2 times / week
Route: intravenous
Route: multiple
Dose: 32 mg/m2, 2 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/20111068
Sourcing

Sourcing

Vendor/AggregatorIDURL
abcr GmbH
AB200576
http://www.abcr.com/shop/en/AB200576
Achemtek
0101-002334
http://www.achemtek.com/467214-20-6
Acorn PharmaTech
ACN-046374
http://www.acornpharmatech.com/
Active Biopharma
ABP000223
http://www.activebiopharma.com/150270-08-9
Active Biopharma
ABP000584
http://www.activebiopharma.com/467214-21-7
AK Scientific, Inc. (AKSCI)
X8446
http://www.aksci.com/item_detail.php?cat=X8446
Aurora Fine Chemicals LLC
A13.105.467
http://online.aurorafinechemicals.com/info?ID=A13.105.467
Aurum Pharmatech LLC
W-5374
http://www.Aurumpharmatech.com/Product/ProductDetails/W_5374
AvaChem Scientific
6006
https://www.avachem.com/productSearch.asp?6006
BioCrick
BCC1346
http://www.biocrick.com/Alvespimycin-BCC1346.html
BOC Sciences
150270-08-9
https://www.bocsci.com/17-dimethylaminoethylamino-17-demethoxygeldanamycin-cas-150270-08-9-item-122708.html
Chem Scene
CS-0912
http://www.chemscene.com/467214-20-6.html
ChemMol
99046992
http://www.chemmol.com/chemmol/99046992.html
ChemShuttle
159942
http://www.chemshuttle.com/catalogsearch/result/?q=467214-20-6&cat=
Chemspace
CSSB00116207116
https://chem-space.com/CSSB00116207116
DC Chemicals
DC36820
http://www.dcchemicals.com//product_show-Alvespimycin.html
eNovation Chemicals
D567341
https://www.enovationchem.com/ProductDetails.asp?ProductID=D567341
eNovation Chemicals
Y1012794
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1012794
Excenen
EX-A1103
http://www.excenen.com/searchresultlist.php?id=467214-20-6
Hairui
HR116175
http://www.hairuichem.com/en/product/467214-20-6.html
Matrix Scientific
89480
https://www.matrixscientific.com/089480.html
MedChem Express
HY-10389
https://www.medchemexpress.com/alvespimycin.html
MolPort
MolPort-006-666-027
https://www.molport.com/shop/molecule-link/MolPort-006-666-027
MuseChem
I003618
https://www.musechem.com/product/I003618.html
MuseChem
M097169
https://www.musechem.com/product/M097169.html
Oakwood
M03709
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=128507&ExtHyperLink=1
OChem
26905
http://www.ocheminc.com/index.php?act=psearch&pid=214D206
Smolecule
S518217
http://www.smolecule.com/products/s518217
THE BioTek
bt-258596
https://www.thebiotek.com/product/inhibitors/bt-258596
PubMed

PubMed

TitleDatePubMed
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
2012-09-01
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
2011-07
Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta.
2010-01-20
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.
2009-07
Heat shock protein inhibitors, 17-DMAG and KNK437, enhance arsenic trioxide-induced mitotic apoptosis.
2009-04-15
Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
2006-11-01
The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins.
2006-10
Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90.
2003-04
Patents

Patents

20050026894
3

Sample Use Guides

In Vivo Use Guide
Phase 1 study. Patients with advanced acute myeloid leukemia (AML) received escalating doses of intravenous alvespimycin (8-32 mg/m(2)), twice weekly, for 2 of 3 weeks. Alvespimycin was well tolerated; the maximum-tolerated dose was 24 mg/m(2) twice weekly. Common toxicities included neutropenic fever, fatigue, nausea and diarrhea. Cardiac DLTs occurred at 32 mg/m(2) (elevated troponin and myocardial infarction). Pharmacokinetics revealed linear increases in C(max) and area under the curve (AUC) from 8 to 32 mg/m(2) and minor accumulation upon repeated doses. Recommended phase 2 dose is 24 mg/m(2).
Route of Administration: Intravenous
In Vitro Use Guide
One hepatic cell line (L02) and two HCC cell lines (Huh7 and HepG2) were heated at 42 °C for 0, 0.5 or 4 h with or without 100 nM alvespimycin (17-DMAG).
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:27:35 GMT 2025
Edited
by admin
on Mon Mar 31 18:27:35 GMT 2025
Record UNII
001L2FE0M3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALVESPIMYCIN
INN   WHO-DD  
INN  
Official Name English
NSC-707545
Preferred Name English
Alvespimycin [WHO-DD]
Common Name English
alvespimycin [INN]
Common Name English
(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-((2-(DIMETHYLAMINO)ETHYL)AMINO)-13-HYDROXY-8,14-DIMETHOXY-4,10,12,16-TETRAMETHYL-3,20,22-TRIOXO-2-AZABICYCLO(16.3.1)DOCOSA-1(21),4,6,10,18-PENTAEN-9-YL CARBAMATE
Common Name English
GELDANAMYCIN, 17-DEMETHOXY-17-((2-(DIMETHYLAMINO)ETHYL)AMINO)-
Common Name English
DMAG
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2516
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C38142
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
PRIMARY
INN
8811
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
PRIMARY
PUBCHEM
5288674
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
PRIMARY
FDA UNII
001L2FE0M3
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
PRIMARY
NSC
707545
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
PRIMARY
EPA CompTox
DTXSID00963646
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
PRIMARY
MESH
C448659
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
PRIMARY
CHEBI
65324
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
PRIMARY
WIKIPEDIA
17-Dimethylaminoethylamino-17-demethoxygeldanamycin
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
PRIMARY
SMS_ID
100000127463
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
PRIMARY
DRUG BANK
DB12442
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
PRIMARY
CAS
467214-20-6
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
PRIMARY
ChEMBL
CHEMBL383824
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
PRIMARY
EVMPD
SUB33529
Created by admin on Mon Mar 31 18:27:35 GMT 2025 , Edited by admin on Mon Mar 31 18:27:35 GMT 2025
PRIMARY
Related Record Type Details
Structure of ALVESPIMYCIN HYDROCHLORIDE
SALT/SOLVATE -> PARENT
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
CYTOCHROME P450 2A6
METABOLIC ENZYME -> SUBSTRATE
MINOR
CYTOCHROME P450 2C8
METABOLIC ENZYME -> SUBSTRATE
MINOR
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
MINOR
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
MINOR
CYTOCHROME P450 3A5
METABOLIC ENZYME -> SUBSTRATE
MAJOR
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
Structure of 17-DEMETHOXY-17-((E)-(2-(DIMETHYLAMINO)ETHYLIDENE)AMINO) GELDANAMYCIN
METABOLITE -> PARENT
IN VITRO
Structure of 17-DEMETHOXY-17-((2-(DIMETHYLAMINO)ETHYL)AMINO)-27-HYDROXYGELDANAMYCIN
METABOLITE -> PARENT
IN VITRO
Structure of 17-DEMETHOXY-12-O-DEMETHYL-17-((2-(DIMETHYLAMINO)ETHYL)AMINO) GELDANAMYCIN
METABOLITE -> PARENT
IN VITRO
IN-VITRO
Structure of 17-DEMETHOXY-17-((2-(DIMETHYLAMINO)ETHYL)AMINO)-6-O-DEMETHYL GELDANAMYCIN
METABOLITE -> PARENT
IN VITRO
Structure of 17-DEMETHOXY-17-((2-(DIMETHYLAMINO)-1-HYDROXYETHYL)AMINO)-28,30-DIHYDROXY GELDANAMYCIN
METABOLITE -> PARENT
IN VITRO
Structure of 17-DEMETHOXY-17-((2-(DIMETHYLAMINO)-1-HYDROXYETHYL)AMINO) GELDANAMYCIN
METABOLITE -> PARENT
IN VITRO
Related Record Type Details
Structure of ALVESPIMYCIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966